Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.52 |
| ▸ | KDR | P35968 | 6/20 | 0.52 |
| ▸ | LCK | P06239 | 5/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 7/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523486 | 0.95 | MAPK14 (0.57) | MAPK14KDRLCKCSF1RKIT | |
| SCHEMBL3520197 | 0.85 | MAPK14 (0.60) | ABL1MAPK14KDRLCKCSF1R | |
| SCHEMBL3520802 | 0.84 | MAPK14 (0.59) | ABL1MAPK14KDRLCKCSF1R | |
| SCHEMBL3523117 | 0.84 | MAPK14 (0.58) | MAPK14KDRLCKCSF1RKIT | |
| SCHEMBL3526945 | 0.82 | MAPK13 (0.53) | MAPK14MAPK13 | |
| SCHEMBL2213889 | 0.82 | MAPK14 (0.50) | MAPK14KDRLCKCSF1RRIPK2 | |
| SCHEMBL3524200 | 0.82 | MAPK14 (0.54) | MAPK14KDRLCKCSF1RKIT | |
| SCHEMBL3524964 | 0.81 | MAPK14 (0.55) | MAPK14KDRLCKCSF1RKIT | |
| SCHEMBL3523058 | 0.81 | MAPK14 (0.56) | MAPK14KDRLCKCSF1RKIT | |
| SCHEMBL3524628 | 0.81 | MAPK14 (0.55) | MAPK14KDRLCKCSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1531812-B1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |